A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer
A Open-label, Single-arm, Phase II Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Forventet)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Hongqing Zhuang, Doctor
- Telefonnummer: 010-82264931
- E-post: hongqingzhuang@163.com
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina, 100191
- Peking University Third Hospital
-
Ta kontakt med:
- Hongqing Zhuang, Doctor
- E-post: hongqingzhuang@163.com
-
Hovedetterforsker:
- Hongqing Zhuang, Doctor
-
Beijing, Beijing, Kina, 100142
- Beijing Cancer Hospital
-
Ta kontakt med:
- Huiming Yu, Doctor
-
Hovedetterforsker:
- Huiming Yu, Doctor
-
-
Shanghai
-
Shanghai, Shanghai, Kina, 200040
- Huashan Hospital Fudan University
-
Ta kontakt med:
- Enmin Wang, Doctor
-
Hovedetterforsker:
- Enmin Wang, Doctor
-
-
Tianjin
-
Tianjin, Tianjin, Kina, 300060
- Tianjin Medical University Cancer Institute and Hospital
-
Ta kontakt med:
- Zhiyong Yuan, Doctor
-
Hovedetterforsker:
- Zhiyong Yuan, Doctor
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
1. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2; Life expectancy ≥ 3 months.
2. Histologically or pathologically confirmed advanced non-small cell lung cancer.
3. Primary lesion controlled oligometastatic patients, the number of metastatic lesions ≤ 5, and has at least one measurable lesion.
4. Has received standard first-line chemotherapy, intolerable or inappropriate to the chemotherapy.
5. Adequate organ system function. 6. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ；No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the first administration.
7.Understood and Signed an informed consent form.
Exclusion Criteria:
1. Has used against PD-1, PD-L1 and other related immunotherapeutic drugs. 2.Has mutations in (epidermal growth factor receptor)EGFR, (anaplastic lymphoma kinase)ALK, (c-ros oncogene 1 receptor kinase)ROS1 or T790M and not resistant to targeted drug.
3. Has severe hypersensitivity reaction to other monoclonal antibodies. 4. Has diagnosed and/or treated additional malignancy within 5 years prior to the first administration.Exceptions include cured basal cell carcinoma of skin and carcinoma in situ of cervix.
5. Has any active autoimmune disease or a history of autoimmune disease. 6. Immunosuppressive therapy with immunosuppressive agents or systemic or absorbable local hormones (dosage > 10 mg/day prednisone or other therapeutic hormones) is required for the purpose of immunosuppression, and is still in use for 2 weeks after the first administration.
7. (Magnetic Resonance Imaging)MRI examination found meningeal metastases and cannot be controlled by stereotactic radiotherapy.
8. Has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1.
9. Has any severe and/or uncontrolled disease. 10. Has vaccinated with vaccines or attenuated vaccines within 4 weeks prior to first administration.
11. According to the judgement of the researchers, there are other factors that may lead to the termination of the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: TQB2450+SBRT
SBRT three days before TQB2450.
|
TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.
Give according to the location of the lesion and clinical condition.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-Free Survival (PFS)
Tidsramme: Baseline up to 96 weeks
|
PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause.
|
Baseline up to 96 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective response rate (ORR)
Tidsramme: Baseline up to 96 weeks
|
Percentage of subjects achieving complete response (CR) and partial response (PR).
|
Baseline up to 96 weeks
|
|
Overall survival (OS)
Tidsramme: Baseline up to 96 weeks
|
OS defined as the time from the first dose to death from any cause.
Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.
|
Baseline up to 96 weeks
|
|
Disease control rate（DCR）
Tidsramme: Baseline up to 96 weeks
|
Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).
|
Baseline up to 96 weeks
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- TQB2450-II-05
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .